At least one drugmaker is planning to submit for FDA approval of its KRAS inhibitor based on data from Phase I/II, single-arm trial in heavily pretreated lung cancer patients.
The institute has recommended the drug as a cost-effective use of NHS resources following submission of new evidence and reflecting a confidential price discount arrangement.
The companies will develop analytics tools and leverage the Syapse Learning Health Network in an effort to shorten the time to market for new cancer therapies.
